Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) has a beta value of 1.39 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $58.18M, closed the last trade at $0.75 per share which meant it gained $0.08 on the day or 12.33% during that session. The HEPA stock price is -77.33% off its 52-week high price of $1.33 and 65.33% above the 52-week low of $0.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.04 million shares traded. The 3-month trading volume is 719.52K shares.
The consensus among analysts is that Hepion Pharmaceuticals Inc. (HEPA) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) trade information
Sporting 12.33% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the HEPA stock price touched $0.75 or saw a rise of 37.12%. Year-to-date, Hepion Pharmaceuticals Inc. shares have moved 148.75%, while the 5-day performance has seen it change -19.51%. Over the past 30 days, the shares of Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) have changed 140.27%. Short interest in the company has seen 0.65 million shares shorted with days to cover at 5.27.
Wall Street analysts have a consensus price target for the stock at $3.25, which means that the shares’ value could jump 76.92% from current levels. The projected low price target is $2.50 while the price target rests at a high of $4.00. In that case, then, we find that the current price level is -433.33% off the targeted high while a plunge would see the stock gain -233.33% from current levels.
Hepion Pharmaceuticals Inc. (HEPA) estimates and forecasts
Figures show that Hepion Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 23.94% over the past 6 months, with this year growth rate of -31.91%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -41.70% and -38.50% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 68.20% over the past 5 years.
Hepion Pharmaceuticals Inc. is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)’s Major holders
Insiders own 0.15% of the company shares, while shares held by institutions stand at 9.88% with a share float percentage of 9.90%. Investors are also buoyed by the number of investors in a company, with Hepion Pharmaceuticals Inc. having a total of 40 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 3.31 million shares worth more than $1.89 million. As of Jun 29, 2022, Vanguard Group, Inc. (The) held 4.34% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 1.61 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $0.92 million and represent 2.12% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.72% shares in the company for having 2.07 million shares of worth $1.19 million while later fund manager owns 1.09 million shares of worth $0.62 million as of Jun 29, 2022, which makes it owner of about 1.43% of company’s outstanding stock.